×
About 5,718 results

ALLMedicine™ Angina Pectoris Center

Research & Reviews  1,327 results

Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications
https://onlinelibrary.wiley.com/doi/abs/10.1111/fcp.12633
Fundamental & Clinical Pharmacology; Ala M, .

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

Increased deformation of the left ventricle during exercise test measured by global lon...
https://doi.org/10.1111/echo.15295
Echocardiography (Mount Kisco, N.Y.); Karlsen S, Melichova D et. al.

Jan 20th, 2022 - Noninvasive identification of significant coronary artery disease (CAD) in patients with unstable angina pectoris (UAP) is challenging. Exercise stress testing has been used for years in patients with suspected CAD but has low diagnostic accuracy....

Sex Difference in the Association between Lipid Profile and Incident Cardiovascular Dis...
https://doi.org/10.5551/jat.63166
Journal of Atherosclerosis and Thrombosis; Kamon T, Kaneko H et. al.

Jan 12th, 2022 - Using a nationwide epidemiological database, we sought to examine whether there was a sex difference in the association between lipid profiles and subsequent cardiovascular disease (CVD) in young adults. Medical records of 1,909,362 young adults (...

Functional Assessment by Virtual Online Reconstruction. The FAVOR III Europe Japan Study
https://clinicaltrials.gov/ct2/show/NCT03729739

Jan 12th, 2022 - Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography (CAG). Lesions are often quantified by visual assessment of the angiogram, but physiological assessment of the functional signif...

see more →

Guidelines  3 results

Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications
https://onlinelibrary.wiley.com/doi/abs/10.1111/fcp.12633
Fundamental & Clinical Pharmacology; Ala M, .

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood...
https://doi.org/10.1016/j.cjca.2016.02.066
The Canadian Journal of Cardiology; Leung AA, Nerenberg K et. al.

Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...

Recommendations for advancing the care of Canadians living with refractory angina pecto...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723022
The Canadian Journal of Cardiology; McGillion M, L'Allier PL et. al.

Jul 9th, 2009 - Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement.|2009|McGillion M,L'Allier PL,Arthur H,Watt-Watson J,Svorkdal N,|epidemiology,therapy,epidemiology,

see more →

Drugs  759 results see all →

Clinicaltrials.gov  92 results

Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications
https://onlinelibrary.wiley.com/doi/abs/10.1111/fcp.12633
Fundamental & Clinical Pharmacology; Ala M, .

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

Functional Assessment by Virtual Online Reconstruction. The FAVOR III Europe Japan Study
https://clinicaltrials.gov/ct2/show/NCT03729739

Jan 12th, 2022 - Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography (CAG). Lesions are often quantified by visual assessment of the angiogram, but physiological assessment of the functional signif...

Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
https://clinicaltrials.gov/ct2/show/NCT02617550

Dec 29th, 2021 - This study is intended to investigate the effect of nitroglycerin on vericiguat in patients with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat acute crisis of angina. Thus there is a high likelihood of co-adm...

The Effect of Antihypertensive Medication Timing on Morbidity and Mortality
https://clinicaltrials.gov/ct2/show/NCT02990663

Dec 10th, 2021 - THE OPPORTUNITY BEDTIME PRESCRIBING MIGHT PROVIDE: Blood pressure normally exhibits a circadian rhythm with relatively lower pressures during sleep.(Ref 1) Lack of this sleep time "dip" correlates strongly with adverse cardiovascular events and BP...

The Impact of Early Cardiac Rehabilitation of AMI Patients on the Incidence of Post-infarction HF
https://clinicaltrials.gov/ct2/show/NCT03528382

Nov 8th, 2021 - Study design: After admission, and following clinical and diagnostic evaluation (12-lead electrocardiogram, Doppler echocardiography, symptom-limited cardiopulmonary exercise test and other related laboratory tests), all patients are discharged in...

see more →

News  101 results

Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications
https://onlinelibrary.wiley.com/doi/abs/10.1111/fcp.12633
Fundamental & Clinical Pharmacology; Ala M, .

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

Hypertension With Right Subclavian Plaque Tied to CV Events
https://www.medscape.com/viewarticle/965796

Dec 30th, 2021 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaways The study demonstrates that the prevalence of right subclavian plaques is an independent risk factor for future c...

Darolutamide Plus Docetaxel/ADT Significantly Improves OS in Metastatic Hormone-Sensitive Prostate Cancer
https://www.onclive.com/view/darolutamide-plus-docetaxel-adt-significantly-improves-os-in-metastatic-hormone-sensitive-prostate-cancer

Dec 3rd, 2021 - The addition of darolutamide (Nubeqa) to docetaxel and androgen deprivation therapy (ADT) resulted in a significant improvement in overall survival (OS) compared with docetaxel/ADT alone in patients with metastatic hormone-sensitive prostate cance...

Home Infusion Trend Stirs Debate
https://www.onclive.com/view/home-infusion-trend-stirs-debate

Nov 24th, 2021 - The COVID-19 pandemic spurred the launching or expansion of in-home cancer therapy infusion programs at several oncology centers around the United States, drawing a surge of interest throughout the field as well as opposition from oncologists who ...

MHRA Updates Safety Information On Tofacitinib
https://www.medscape.com/viewarticle/960411

Oct 7th, 2021 - The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update for tofacitinib (Xeljanz) stating that individuals aged >65 years, current or past smokers or individuals with other cardiovascular or malignancy risk f...

see more →

Patient Education  5 results see all →